BioXcel Therapeutics, Inc.

NasdaqCM:BTAI Rapporto sulle azioni

Cap. di mercato: US$26.2m

BioXcel Therapeutics Gestione

Gestione criteri di controllo 2/4

BioXcel Therapeutics' CEO is Vimal Mehta, appointed in May 2017, has a tenure of 7.5 years. total yearly compensation is $4.73M, comprised of 21.2% salary and 78.8% bonuses, including company stock and options. directly owns 0.13% of the company’s shares, worth $34.51K. The average tenure of the management team and the board of directors is 7.1 years and 6.3 years respectively.

Informazioni chiave

Vimal Mehta

Amministratore delegato

US$4.7m

Compenso totale

Percentuale dello stipendio del CEO21.2%
Mandato del CEO7.5yrs
Proprietà del CEO0.1%
Durata media del management7.1yrs
Durata media del Consiglio di amministrazione6.3yrs

Aggiornamenti recenti sulla gestione

Shareholders May Be More Conservative With BioXcel Therapeutics, Inc.'s (NASDAQ:BTAI) CEO Compensation For Now

Jun 04
Shareholders May Be More Conservative With BioXcel Therapeutics, Inc.'s (NASDAQ:BTAI) CEO Compensation For Now

Recent updates

Shareholders May Be More Conservative With BioXcel Therapeutics, Inc.'s (NASDAQ:BTAI) CEO Compensation For Now

Jun 04
Shareholders May Be More Conservative With BioXcel Therapeutics, Inc.'s (NASDAQ:BTAI) CEO Compensation For Now

BioXcel Therapeutics: Igalmi's Commercial Uncertainty Remains, Downgrading To A Hold

Aug 28

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Vimal Mehta rispetto agli utili di BioXcel Therapeutics?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

-US$108m

Mar 31 2024n/an/a

-US$153m

Dec 31 2023US$5mUS$1m

-US$179m

Sep 30 2023n/an/a

-US$212m

Jun 30 2023n/an/a

-US$203m

Mar 31 2023n/an/a

-US$187m

Dec 31 2022US$5mUS$944k

-US$166m

Sep 30 2022n/an/a

-US$137m

Jun 30 2022n/an/a

-US$122m

Mar 31 2022n/an/a

-US$112m

Dec 31 2021US$9mUS$917k

-US$107m

Sep 30 2021n/an/a

-US$102m

Jun 30 2021n/an/a

-US$100m

Mar 31 2021n/an/a

-US$94m

Dec 31 2020US$10mUS$890k

-US$82m

Sep 30 2020n/an/a

-US$69m

Jun 30 2020n/an/a

-US$54m

Mar 31 2020n/an/a

-US$41m

Dec 31 2019US$2mUS$459k

-US$33m

Sep 30 2019n/an/a

-US$32m

Jun 30 2019n/an/a

-US$28m

Mar 31 2019n/an/a

-US$22m

Dec 31 2018US$702kUS$423k

-US$19m

Sep 30 2018n/an/a

-US$15m

Jun 30 2018n/an/a

-US$11m

Mar 31 2018n/an/a

-US$8m

Dec 31 2017US$284kUS$147k

-US$5m

Compensazione vs Mercato: Vimal's total compensation ($USD4.73M) is above average for companies of similar size in the US market ($USD655.02K).

Compensazione vs guadagni: Vimal's compensation has increased whilst the company is unprofitable.

AMMINISTRATORE DELEGATO

Vimal Mehta (63 yo)

7.5yrs

Mandato

US$4,731,147

Compensazione

Dr. Vimal D. Mehta, Ph D., is Co-Founder of BioXcel Corporation and following its inception in 2005, has served as its Chairman and Chief Executive Officer. Dr. Mehta served as a Director at Invea Therapeu...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Vimal Mehta
Founder7.5yrsUS$4.73m0.13%
$ 34.5k
Javier Rodriguez
Senior VP3.8yrsUS$1.12m0.058%
$ 15.3k
Richard Steinhart
Senior VP & CFO7.1yrsUS$404.00k0.050%
$ 13.0k
Frank Yocca
Senior VP & Chief Scientific Officer7.4yrsUS$1.15m0.069%
$ 18.2k
Vincent O'Neill
Executive VP and Chief of Product Development & Medical Officer7.3yrsUS$510.17k0.048%
$ 12.6k
Chetan Lathia
Senior VP and Head of Translational Medicine2.3yrsNessun datoNessun dato
Robert Risinger
Chief Medical Officer - Neuroscience2.8yrsNessun datoNessun dato

7.1yrs

Durata media

63yo

Età media

Gestione esperta: BTAI's management team is seasoned and experienced (7.1 years average tenure).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Vimal Mehta
Founder7.6yrsUS$4.73m0.13%
$ 34.5k
Steven Paul
Member of Advisory Boardno dataNessun datoNessun dato
Peter Mueller
Independent Chairman & Lead Director7.6yrsUS$367.33k0.57%
$ 149.6k
Alan Breier
Member of Clinical Advisory Board6.3yrsNessun datoNessun dato
Thomas Laughren
Member of Clinical Advisory Board5.8yrsNessun datoNessun dato
Maurizio Fava
Member of Clinical Advisory Board5.8yrsNessun datoNessun dato
Stephen Marder
Member of Clinical Advisory Board6.3yrsNessun datoNessun dato
Sheldon Preskorn
Member of Clinical Advisory Board6.3yrsNessun datoNessun dato
John Krystal
Member of Clinical Advisory Board5.8yrsNessun datoNessun dato
Sandeep Laumas
Independent Director7.2yrsUS$329.83k0%
$ 0
Sheila Gujrathi
Member of Advisory Boardno dataNessun datoNessun dato
George Grossberg
Member of Clinical Advisory Board6.3yrsNessun datoNessun dato

6.3yrs

Durata media

63yo

Età media

Consiglio di amministrazione esperto: BTAI's board of directors are considered experienced (6.3 years average tenure).